NO20021959D0 - Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer - Google Patents

Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer

Info

Publication number
NO20021959D0
NO20021959D0 NO20021959A NO20021959A NO20021959D0 NO 20021959 D0 NO20021959 D0 NO 20021959D0 NO 20021959 A NO20021959 A NO 20021959A NO 20021959 A NO20021959 A NO 20021959A NO 20021959 D0 NO20021959 D0 NO 20021959D0
Authority
NO
Norway
Prior art keywords
tetrahydrotiopyranephthalazinone
derivatives
pde4 inhibitors
pde4
inhibitors
Prior art date
Application number
NO20021959A
Other languages
English (en)
Other versions
NO20021959L (no
Inventor
Armin Hatzelmann
Daniela Bundschuh
Hans-Peter Kley
Geert Jan Sterk
Ivonne Johanna Van Der Laan
Hendrik Timmerman
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of NO20021959D0 publication Critical patent/NO20021959D0/no
Publication of NO20021959L publication Critical patent/NO20021959L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20021959A 1999-10-25 2002-04-25 Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer NO20021959L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99121243 1999-10-25
US20395000P 2000-05-12 2000-05-12
PCT/EP2000/010445 WO2001030777A1 (en) 1999-10-25 2000-10-24 Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors

Publications (2)

Publication Number Publication Date
NO20021959D0 true NO20021959D0 (no) 2002-04-25
NO20021959L NO20021959L (no) 2002-05-29

Family

ID=26153155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021959A NO20021959L (no) 1999-10-25 2002-04-25 Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer

Country Status (20)

Country Link
US (2) US6544993B1 (no)
EP (1) EP1244654A1 (no)
JP (1) JP2003512466A (no)
KR (1) KR20020043238A (no)
CN (1) CN1146562C (no)
AU (1) AU781137B2 (no)
BR (1) BR0014990A (no)
CA (1) CA2388119A1 (no)
CZ (1) CZ20021457A3 (no)
EA (1) EA005856B1 (no)
HK (1) HK1047276A1 (no)
HR (1) HRP20020350A2 (no)
HU (1) HUP0203487A2 (no)
IL (1) IL148807A0 (no)
MX (1) MXPA02003581A (no)
NO (1) NO20021959L (no)
PL (1) PL354979A1 (no)
SK (1) SK7232002A3 (no)
TR (1) TR200201128T2 (no)
WO (1) WO2001030777A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020350A2 (en) * 1999-10-25 2004-02-29 Altana Pharma Ag Tetrahydrothiopy ranphtalazinone derivatives as pde4 inhibitors
JP4301812B2 (ja) * 2001-02-15 2009-07-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしてのフタラインオン−ピペリジノ−誘導体
PL363544A1 (en) * 2001-04-25 2004-11-29 Altana Pharma Ag Piperazino-derivatives and their use as pde4 inhibitor
SK14342003A3 (sk) 2001-04-25 2004-05-04 Altana Pharma Ag Ftalazinóny, farmaceutický prostriedok s ich obsahom a ich použitie
TWI347845B (en) * 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
CA2494643A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-n-oxide-derivatives
WO2004018449A1 (en) * 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
DE60313472T2 (de) * 2002-08-10 2008-01-24 Nycomed Gmbh Pyrrolidindion-substituierte piperidin-phthalazone als pde4-inhibitoren
EP1556369A1 (en) * 2002-08-10 2005-07-27 ALTANA Pharma AG Pyridazinone-derivatives as pde4 inhibitors
CA2512819A1 (en) * 2003-01-14 2004-07-29 Altana Pharma Ag Pde4 inhibitors for the treatment of neoplasms of lymphoid cells
EP1716133B1 (en) 2004-02-04 2008-03-26 Nycomed GmbH 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-one derivatives as pde4 inhibitors
US20080227790A1 (en) * 2004-02-04 2008-09-18 Altana Pharma Ag Pyridazinone Derivatives and their Use as Pde4 Inhibitors
CN104803973A (zh) * 2004-03-03 2015-07-29 塔科达有限责任公司 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途
JP5927201B2 (ja) * 2010-12-16 2016-06-01 カルチャン リミテッド Ａｓｋ１阻害ピロロピリミジン誘導体
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9204808D0 (en) * 1992-03-04 1992-04-15 Rhone Poulenc Rorer Ltd Novel compositions of matter
WO1994012461A1 (en) 1992-12-02 1994-06-09 Pfizer Inc. Catechol diethers as selective pdeiv inhibitors
DE19533975A1 (de) 1995-09-14 1997-03-20 Merck Patent Gmbh Arylalkyl-diazinone
CZ293815B6 (cs) 1997-01-15 2004-08-18 Altanaápharmaáag Ftalazinonové deriváty
AU1760399A (en) 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
US6380196B1 (en) 1997-12-15 2002-04-30 Byk Gulden Lomberg Chemische Fabrik Gmbh Dihydrobenzofurans
AU3328499A (en) 1998-03-14 1999-10-11 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone pde iii/iv inhibitors
HRP20020350A2 (en) * 1999-10-25 2004-02-29 Altana Pharma Ag Tetrahydrothiopy ranphtalazinone derivatives as pde4 inhibitors

Also Published As

Publication number Publication date
IL148807A0 (en) 2002-09-12
HRP20020350A2 (en) 2004-02-29
SK7232002A3 (en) 2002-09-10
EP1244654A1 (en) 2002-10-02
TR200201128T2 (tr) 2002-08-21
CN1382137A (zh) 2002-11-27
EA200200381A1 (ru) 2002-10-31
BR0014990A (pt) 2002-06-18
KR20020043238A (ko) 2002-06-08
HK1047276A1 (zh) 2003-02-14
HUP0203487A2 (hu) 2003-02-28
US6544993B1 (en) 2003-04-08
AU1515101A (en) 2001-05-08
AU781137B2 (en) 2005-05-05
PL354979A1 (en) 2004-03-22
CN1146562C (zh) 2004-04-21
US20030166655A1 (en) 2003-09-04
NO20021959L (no) 2002-05-29
WO2001030777A1 (en) 2001-05-03
EA005856B1 (ru) 2005-06-30
CA2388119A1 (en) 2001-05-03
US6846821B2 (en) 2005-01-25
JP2003512466A (ja) 2003-04-02
CZ20021457A3 (cs) 2002-07-17
MXPA02003581A (es) 2002-10-23

Similar Documents

Publication Publication Date Title
DK1244647T3 (da) Quinzolinderivater som VIGF-inhibitorer
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
NO20021239D0 (no) Pteridinoner som kinase-inhibitorer
NO20030867L (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
NO20015065D0 (no) Pyrazolobenzodiazepiner som CDK2-inhibitorer
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20030055L (no) Colchinolderivater som angiogenese inhibitorer
NO20014642D0 (no) Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer
NO20021329D0 (no) Kinaseinhibitorer som terapeutiske midler
DK1289985T3 (da) Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
ATE237329T1 (de) Metalloprotease inhibitoren
NO20033618D0 (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
NO20025811D0 (no) Forbindelser som er effektive som beta-2-adrenoreseptor- anonister så vel som PDE4-inhibitorer
NO20021407L (no) Bifenylderivater anvendt som NHE-3-inhibitorer
DK1226143T3 (da) Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1183251T3 (da) Indolylpiperidinderivater som antihistamin- og antiallergimidler
NO20021959L (no) Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20014243L (no) Dihetero-substituerte metalloproteaseinhibitorer
NO20023001D0 (no) Substituerte piperazinderivater som MTP inhibitorer
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
DE60009260D1 (de) Thiopyranderivate as mmp-inhibitoren
NO20020592D0 (no) Fluorenderivater som integrininhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application